9 results on '"van der Laan, Hans P."'
Search Results
2. Sparing the region of the salivary gland containing stem cells preserves saliva production after radiotherapy for head and neck cancer
- Author
-
van Luijk, Peter, Pringle, Sarah, Deasy, Joseph O, Moiseenko, Vitali V, Faber, Hette, Hovan, Allan, Baanstra, Mirjam, van der Laan, Hans P, Kierkels, Roel GJ, van der Schaaf, Arjen, Witjes, Max J, Schippers, Jacobus M, Brandenburg, Sytze, Langendijk, Johannes A, Wu, Jonn, and Coppes, Robert P
- Subjects
Stem Cell Research - Nonembryonic - Human ,Regenerative Medicine ,Transplantation ,Stem Cell Research - Nonembryonic - Non-Human ,Stem Cell Research ,Cancer ,Dental/Oral and Craniofacial Disease ,Digestive Diseases ,Evaluation of treatments and therapeutic interventions ,6.5 Radiotherapy and other non-invasive therapies ,Animals ,Head and Neck Neoplasms ,Humans ,Mice ,Parotid Gland ,Quality of Life ,Radiotherapy ,Rats ,Saliva ,Salivary Glands ,Stem Cells ,Xerostomia ,Biological Sciences ,Medical and Health Sciences - Abstract
Each year, 500,000 patients are treated with radiotherapy for head and neck cancer, resulting in relatively high survival rates. However, in 40% of patients, quality of life is severely compromised because of radiation-induced impairment of salivary gland function and consequent xerostomia (dry mouth). New radiation treatment technologies enable sparing of parts of the salivary glands. We have determined the parts of the major salivary gland, the parotid gland, that need to be spared to ensure that the gland continues to produce saliva after irradiation treatment. In mice, rats, and humans, we showed that stem and progenitor cells reside in the region of the parotid gland containing the major ducts. We demonstrated in rats that inclusion of the ducts in the radiation field led to loss of regenerative capacity, resulting in long-term gland dysfunction with reduced saliva production. Then we showed in a cohort of patients with head and neck cancer that the radiation dose to the region of the salivary gland containing the stem/progenitor cells predicted the function of the salivary glands one year after radiotherapy. Finally, we showed that this region of the salivary gland could be spared during radiotherapy, thus reducing the risk of post-radiotherapy xerostomia.
- Published
- 2015
3. Whole breast proton irradiation for maximal reduction of heart dose in breast cancer patients
- Author
-
Mast, Mirjam E., Vredeveld, Eline J., Credoe, Herman M., van Egmond, Jaap, Heijenbrok, Mark W., Hug, Eugen B., Kalk, Patrick, van Kempen-Harteveld, Loes M. L., Korevaar, Erik W., van der Laan, Hans Paul, Langendijk, Johannes A., Rozema, Hans J. E., Petoukhova, Anna L., Schippers, Jacobus M., Struikmans, Henk, and Maduro, John H.
- Published
- 2014
- Full Text
- View/download PDF
4. Dosimetric consequences of the shift towards computed tomography guided target definition and planning for breast conserving radiotherapy
- Author
-
Korevaar Erik W, Maduro John H, Dolsma Wil V, van der Laan Hans, and Langendijk Johannes A
- Subjects
Medical physics. Medical radiology. Nuclear medicine ,R895-920 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background The shift from conventional two-dimensional (2D) to three-dimensional (3D)-conformal target definition and dose-planning seems to have introduced volumetric as well as geometric changes. The purpose of this study was to compare coverage of computed tomography (CT)-based breast and boost planning target volumes (PTV), absolute volumes irradiated, and dose delivered to the organs at risk with conventional 2D and 3D-conformal breast conserving radiotherapy. Methods Twenty-five patients with left-sided breast cancer were subject of CT-guided target definition and 3D-conformal dose-planning, and conventionally defined target volumes and treatment plans were reconstructed on the planning CT. Accumulated dose-distributions were calculated for the conventional and 3D-conformal dose-plans, taking into account a prescribed dose of 50 Gy for the breast plans and 16 Gy for the boost plans. Results With conventional treatment plans, CT-based breast and boost PTVs received the intended dose in 78% and 32% of the patients, respectively, and smaller volumes received the prescribed breast and boost doses compared with 3D-conformal dose-planning. The mean lung dose, the volume of the lungs receiving > 20 Gy, the mean heart dose, and volume of the heart receiving > 30 Gy were significantly less with conventional treatment plans. Specific areas within the breast and boost PTVs systematically received a lower than intended dose with conventional treatment plans. Conclusion The shift towards CT-guided target definition and planning as the golden standard for breast conserving radiotherapy has resulted in improved target coverage at the cost of larger irradiated volumes and an increased dose delivered to organs at risk. Tissue is now included into the breast and boost target volumes that was never explicitly defined or included with conventional treatment. Therefore, a coherent definition of the breast and boost target volumes is needed, based on clinical data confirming tumour control probability and normal tissue complication probability with the use of 3D-conformal radiotherapy.
- Published
- 2008
- Full Text
- View/download PDF
5. Weekly robustness evaluation of intensity-modulated proton therapy for oesophageal cancer.
- Author
-
Anakotta, R. Melissa, van der Laan, Hans P., Visser, Sabine, Ribeiro, Cassia O., Dieters, Margriet, Langendijk, Johannes A., Both, Stefan, Korevaar, Erik W., Sijtsema, Nanna M., Knopf, Antje, and Muijs, Christina T.
- Subjects
- *
PROTON therapy , *VOLUMETRIC-modulated arc therapy , *CANCER treatment - Abstract
• IMPT accomplishes a significant and consistent dose reduction to OARs. • IMPT has comparable robustness compared to VMAT for oesophageal cancer. • Re-planning was required more often for IMPT compared to VMAT. Intensity-modulated proton therapy (IMPT) is expected to result in clinical benefits by lowering radiation dose to organs-at-risk (OARs). However, there are concerns about plan robustness due to motion. To address this uncertainty we evaluated the robustness of IMPT compared to the widely clinically used volumetric modulated arc therapy (VMAT) on weekly repeated computed tomographies (CT). 19 patients with oesophageal cancer were evaluated. IMPT and VMAT plans were created on a planning 4-Dimensional CT (p4DCT) and evaluated on weekly repeated 4DCTs (r4DCT). In case of inadequate target coverage or unacceptable high dose to normal tissue, re-planning was performed. Dose distributions of the r4DCTs were warped to p4DCT, resulting in an estimated actual given dose (EAGD). Compared to VMAT, IMPT resulted in significantly lowered dose to heart, lungs, spleen, liver and kidneys. For IMPT, target coverage was adequate (after max 1 replanning) in 17/19 cases. In two cases target coverage remained insufficient. However, in one of these patients the summed dose was insufficient (due to tumor shrinkage) while weekly coverage was adequate. For the other patient the target coverage was also insufficient by VMAT, due to large anatomical changes during treatment. For VMAT, adequate target coverage was achieved in 18/19 cases without re-planning. However, for reasons of high OAR dose re-planning was required in two cases. IMPT reduces the dose to OARs significantly, while achieving adequate target coverage in the majority of patients. Re-planning was necessary for both IMPT and VMAT due to anatomical changes. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
6. Effect of painful Ledderhose disease on dynamic plantar foot pressure distribution during walking: a case-control study.
- Author
-
de Haan, Anneke, Hijmans, Juha M., van der Vegt, Anna E., van der Laan, Hans Paul, van Nes, Johanna G.H., Werker, Paul M.N., Langendijk, Johannes A., and Steenbakkers, Roel J.H.M.
- Abstract
Plantar pressure distribution during walking in patients with painful Ledderhose disease is unknown. Do patients with painful Ledderhose disease have an altered plantar pressure distribution during walking compared to individuals without foot pathologies? It was hypothesized that plantar pressure is shifted away from the painful nodules. Pedobarography data of 41 patients with painful Ledderhose disease (cases, mean age: 54.2 ± 10.4 years) was collected and compared to pedobarography data from 41 individuals without foot pathologies (controls, mean age: 21.7 ± 2.0 years). Peak Pressure (PP), Maximum Mean Pressure (MMP) and Force-Time Integral (FTI) were calculated for eight regions (heel, medial midfoot, lateral midfoot, medial forefoot, central forefoot, lateral forefoot, hallux and other toes) under the soles of the feet. Differences between cases and controls were calculated and analysed by means of linear (mixed models) regression. Proportional differences in PP, MMP and FTI showed increased values for the cases compared to the controls, especially in the heel, hallux and other toes regions, and decreased values in the medial- and lateral midfoot regions. In naïve regression analysis, being a patient was a predictor for increased- and decreased values for PP, MMP and FTI for several regions. When dependencies in the data were taken into account with linear mixed-model regression analysis, the increased- and decreased values for the patients were most prevalent for FTI at the heel, medial midfoot, hallux and other toes regions. In patients with painful Ledderhose disease, during walking, a shift of pressure was found towards the proximal and distal foot regions, while offloading the midfoot regions. • Ledderhose disease results in altered plantar pressure distribution. • Offloading of affected midfoot regions during walking. • Increase of load on heel and hallux regions during walking. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. Comparison of normal tissue dose with three-dimensional conformal techniques for breast cancer irradiation including the internal mammary nodes
- Author
-
van der Laan, Hans P., Dolsma, Wil V., van ’t Veld, Aart A., Bijl, Hendrik P., and Langendijk, Johannes A.
- Subjects
- *
BREAST cancer , *HEART diseases , *THERAPEUTICS , *IRRADIATION , *TISSUES - Abstract
Purpose: To compare the Para Mixed technique for irradiation of the internal mammary nodes (IMN) with three commonly used strategies, by analyzing the dose to the heart and other organs at risk. Methods and Materials: Four different three-dimensional conformal dose plans were created for 30 breast cancer patients. The IMN were enclosed with the Para Mixed technique by a widened mediolateral tangent photon beam and an anterior electron beam, with the Patched technique by an anterior electron beam, with the Standard technique by an anterior photon and electron beam, and with the PWT technique by partially wide tangents. All techniques were optimized for conformality and produced equally adequate target coverage. Results: Heart dose was lowest with the Para Mixed and Patched technique for all patients and with the PWT technique for right-sided treatment only. Lung dose was highest with the PWT, lowest with the Patched, and intermediate with the Para Mixed and Standard techniques. Skin dose was highest with the Patched, lowest with the PWT, and intermediate with the Para Mixed and the Standard techniques. The Para Mixed technique resulted in a 13-Gy lower dose in an overlap area, and the PWT technique was the only technique that incorporated considerable volumes of the contralateral breast. Conclusion: The Para Mixed technique yielded the overall best results. No other technique resulted in a lower heart dose. Lung and skin were equally spared instead of one of them being compromised, and the contralateral breast was avoided. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
8. First experience with model-based selection of head and neck cancer patients for proton therapy.
- Author
-
Tambas, Makbule, Steenbakkers, Roel J.H.M., van der Laan, Hans P., Wolters, Atje M., Kierkels, Roel G.J., Scandurra, Dan, Korevaar, Erik W., Oldehinkel, Edwin, van Zon-Meijer, Tineke W.H., Both, Stefan, van den Hoek, Johanna G.M., and Langendijk, Johannes A.
- Subjects
- *
PROTON therapy , *CANCER patients , *HEAD & neck cancer , *HYPOPHARYNGEAL cancer , *PATIENT selection - Abstract
• Model-based selection of patients with HNC for proton is clinically feasible. • Around 35% of HNC patients qualify for protons. • Most patients are selected based on ΔNTCP in dysphagia-related models. • Patients with advanced and pharyngeal tumor have higher probability to be selected. In the Netherlands, head and neck cancer (HNC) patients qualify for intensity modulated proton therapy (IMPT) based on model-based selection (MBS). The aim of this study was to evaluate the first experience in MBS of HNC patients. Patients who were subjected to MBS (Jan 2018–Sep 2019) were evaluated. A VMAT plan was created for all patients with optimal sparing of organ at risks (OARs) in normal tissue complication probability (NTCP) models for a number of toxicities. An IMPT plan was created only for those with NTCP difference (ΔNTCP) between VMAT and best-case scenario for proton (assuming 0 Gy dose for all OARs in IMPT plan) that exceeded any ΔNTCP-thresholds defined in Dutch National Indication Protocol. These patients qualified for a robust IMPT-plan creation with similar target doses and subsequent plan comparison. Of 227 patients, 141 (62%) qualified for plan comparison, of which 80 (35%) were eventually selected for proton therapy. Most patients were selected based on the ΔNTCP for dysphagia-related toxicities. The selection rate was higher among patients with advanced disease, pharyngeal tumors, and/or baseline complaints. A significant reduction in all OAR doses and NTCP values was obtained with IMPT compared with VMAT in both selected and non-selected patients, but more pronounced in patients selected for protons. Model-based selection of patients with HNC for proton therapy is clinically feasible. Approximately one third of HNC patients qualify for protons and these patients have the highest probability to benefit from protons in terms of toxicity prevention. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
9. Impact of sarcopenia on survival and late toxicity in head and neck cancer patients treated with radiotherapy.
- Author
-
van Rijn-Dekker, Maria I., van den Bosch, Lisa, van den Hoek, Johanna G.M., Bijl, Hendrik P., van Aken, Evert S.M., van der Hoorn, Anouk, Oosting, Sjoukje F., Halmos, Gyorgy B., Witjes, Max J.H., van der Laan, Hans P., Langendijk, Johannes A., and Steenbakkers, Roel J.H.M.
- Subjects
- *
HEAD & neck cancer , *CANCER patients , *SARCOPENIA , *SQUAMOUS cell carcinoma , *OROPHARYNGEAL cancer - Abstract
• Sarcopenia is relevant for head and neck cancer patients treated with radiotherapy. • Sarcopenia is an independent adverse prognostic factor for survival outcomes. • For oropharyngeal cancer, survival is more defined by p16 status than by sarcopenia. • Sarcopenia is associated with late radiation-induced toxicities. Sarcopenia is emerging as an adverse prognostic factor for survival and complication risk in cancer patients. This study aims to determine the impact of sarcopenia on survival and late toxicity in a large cohort of head and neck squamous cell carcinoma (HNSCC) patients treated with definitive (chemo)radiotherapy ((C)RT). HNSCC patients treated with definitive (C)RT from January 2007 to June 2016 were included. Sarcopenia was assessed from radiation planning computed tomography (CT) scans using skeletal muscles at level C3. The impact of sarcopenia on overall survival (OS) and disease-free survival (DFS) was evaluated using the Kaplan–Meier method. Multivariable association models were developed to assess the impact of sarcopenia on late toxicity. The study population was composed of 750 HNSCC patients. Cut-off values for sarcopenia were set at SMI < 42.4 cm2/m2 (men) and <30.6 cm2/m2 (women) corresponding lowest gender specific quartile. Sarcopenic patients had significantly poorer survival rates, especially those with lower performance status and locally advanced disease. In oropharyngeal cancer patients, survival was more determined by p16 status than by sarcopenia. In multivariable analysis, sarcopenia was associated with worse OS (HR 0.72, p = 0.012) and DFS (HR 0.67, p = 0.001). In multivariable association models, sarcopenia was associated with physician-rated xerostomia six months after treatment (OR 1.65, p = 0.027) and physician-rated dysphagia six and twelve months after treatment (OR 2.02, p = 0.012 and 2.51, p = 0.003, respectively). Sarcopenia in HNSCC patients receiving definitive (C)RT is an independent prognostic factor for worse survival outcomes and is associated with physician-rated toxicity. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.